SCHEMBL4397520

SCHEMBL4397520

Cc1ccn2ccccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.41
ALDH1A1 P00352 7/20 0.41
HPGD P15428 5/20 0.41
GAA P10253 4/20 0.41
KLK7 P49862 1/20 0.41
ALOX15 P16050 1/20 0.40
TSHR P16473 2/20 0.36
ACHE P22303 1/20 0.36
GLA P06280 1/20 0.34
ALKBH5 Q6P6C2 1/20 0.33
FTO Q9C0B1 1/20 0.33
GPR3 P46089 1/20 0.33
CYP1A2 P05177 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
GRM5 P41594 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethane SCHEMBL10592328 0.98 KDM4E (0.39) KDM4EALDH1A1HPGDGAAKLK7
SCHEMBL4566857 0.84 ALDH1A1 (0.48) KDM4EALDH1A1HPGDGAAKLK7
SCHEMBL8404405 0.78 ALDH1A1 (0.44) KDM4EALDH1A1HPGDGAAKLK7
SCHEMBL31609391 0.74 ALOX15 (0.43) KDM4EALDH1A1HPGDGAAKLK7
SCHEMBL22144532 0.73 SRD5A1 (0.38) KDM4EALDH1A1HPGDGAAKLK7
SCHEMBL7166909 0.71 HRH3 (0.40) KDM4EALDH1A1HPGDGAAKLK7
SCHEMBL29249033 0.70 ALDH1A1 (0.48) KDM4EALDH1A1HPGDGAAKLK7
SCHEMBL2005732 0.70 ALOX15 (0.40) KDM4EALDH1A1HPGDGAAKLK7
SCHEMBL8404409 0.70 KDM4E (0.38) KDM4EALDH1A1GAATSHRACHE
SCHEMBL16915952 0.70 ALOX15 (0.40) KDM4EALDH1A1HPGDGAAKLK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6572664-B2 Oxidation dyeing of keratin fibers L'OREAL S.A. (FR) 2003-06-03 US claimed
US-20020170121-A9 Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same L'OREAL S.A. (FR) 2002-11-21 US claimed
US-20020002749-A1 Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same BRETON PHILIPPE (FR) 2002-01-10 US claimed
EP-1129691-A2 Compositions for dyeing keratinous fibers containing indolizine derivatives and dyeing method using same L'OREAL (FR) 2001-09-05 EP claimed
US-5134239-A Quaterinary indolizine compound THE DOW CHEMICAL COMPANY (US) 1992-07-28 US claimed
EP-0201221-B1 6-(1-ACYL-1-HYDROXY METHYL) PENICILLANIC ACID DERIVATIVES PFIZER INC. (US) 1990-08-01 EP claimed
US-4925901-A STORAGE STAABILITY, ONIUM ION CATALYST THE DOW CHEMICAL COMPANY (US) 1990-05-15 US claimed
US-4762921-A 6-(1-acyl-1-hydroxymethyl)penicillanic acid derivatives PFIZER INC. (US) 1988-08-09 US claimed
US-4675186-A 6-(1-acyl-1-hydroxymethyl)penicillanic acid derivatives PFIZER INC. (US) 1987-06-23 US claimed
EP-0201221-A1 6-(1-acyl-1-hydroxy methyl) penicillanic acid derivatives PFIZER INC. (US) 1986-11-12 EP claimed
US-12202829-B2 Heterocyclic compound FIMECS, INC. (JP) 2025-01-21 US disclosed
US-20230312481-A1 SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF ARBUTUS BIOPHARMA CORP (CA) 2023-10-05 US disclosed
US-20230312481-A1 SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF ARBUTUS BIOPHARMA CORP (CA) 2023-10-05 US disclosed
WO-2023183613-A2 INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR INFLAMMATION TACTOGEN INC (US) 2023-09-28 WO disclosed
US-20230242529-A1 HETEROCYCLIC COMPOUND FIMECS, INC. (JP) 2023-08-03 US disclosed
EP-0068880-A1 Photographic elements capable of providing oxoindolizine and oxoindolizinium dye compounds EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1983-01-05 EP disclosed
EP-0068876-A1 Oxoindolizine and oxoindolizinium dyes and processes for their preparation EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1983-01-05 EP disclosed
EP-0000082-B1 PROCESS FOR IMAGE-WISE MODIFYING THE SURFACE OF AN ETCHABLE SUPPORT AND MATERIAL SUITABLE THEREFOR COMPRISING A COLLOID LAYER CONTAINING POLYMERS WITH OXIME-ESTER GROUPS AGFA-GEVAERT N.V. (BE) 1982-07-21 EP disclosed
US-4202697-A Production of etch-resist colloid and material suitable therefor AGFA-GEVAERT N.V. (BE) 1980-05-13 US disclosed
EP-0000082-A1 Process for image-wise modifying the surface of an etchable support and material suitable therefor comprising a colloid layer containing polymers with oxime-ester groups AGFA-GEVAERT N.V. (BE) 1978-12-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242529-A1 HETEROCYCLIC COMPOUND XIAP, BIRC5, BIRC3 KDM4E 2577/4885ALDH1A1 2510/4885HPGD 947/4885
US-20020002749-A1 Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same KRT18, INMT, IDO1 KDM4E 1225/4885ALDH1A1 897/4885HPGD 273/4885
US-20020170121-A9 Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same KRT18, INMT, IDO1 KDM4E 1225/4885ALDH1A1 897/4885HPGD 273/4885
US-20230312481-A1 SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF NSD3, PML, NSD1 KDM4E 133/4885ALDH1A1 3447/4885HPGD 1773/4885
US-12202829-B2 Heterocyclic compound XIAP, BIRC5, BIRC3 KDM4E 2577/4885ALDH1A1 2510/4885HPGD 947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.